Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by TScan Therapeutics, Inc.

< Previous 1 2 Next >
TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics to Participate in Upcoming Investor Conferences
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers FCNCA TCRX
TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics to Participate in Upcoming Investor Conferences
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics Announces Updates to its Board of Directors
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics Announces Closing of Upsized Public Offering
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.